HemoLife Medical, Inc. is developing proprietary technologies designed to help physicians manage patients with Hepatic Failure, Systemic Inflammatory Response Syndrome (Sepsis) and Acute Renal Failure. The company intends to market devices that remove toxins associated with Hepatic Failure, Sepsis and Renal Failure as well as cytokines, endotoxins and other biochemicals from blood that contribute to significant patient morbidity and mortality. This will assist physicians in their ability to treat these patients in whom current therapies are generally ineffective.

The founders of HemoLife Medical, Inc. bring over 50 years experience in the design and operation of extracorporeal systems as well as advanced developments in biochemistry. Together this expertise has produced cutting edge technology for the detoxification of human plasma during a bedside treatment.